BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 18932097)

  • 1. Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?
    Henriksson R; Bergström P; Johansson M; Sandström M
    Acta Oncol; 2009; 48(1):6-8. PubMed ID: 18932097
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms of evasion to antiangiogenic therapy in glioblastoma.
    Rose SD; Aghi MK
    Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504
    [No Abstract]   [Full Text] [Related]  

  • 3. Bevacizumab antiangiogenic therapy for glioblastoma.
    Junck L
    Neurology; 2011 Feb; 76(5):414-5. PubMed ID: 21282587
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
    Chinot OL
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of avastin in the management of recurrent glioblastoma.
    Sweet JA; Feinberg ML; Sherman JH
    Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optic neuropathy in patients with glioblastoma receiving bevacizumab.
    Chamberlain MC; Raizer J; Schiff D; Sherman JH
    Neurology; 2010 Jul; 75(3):289-90; author reply 290. PubMed ID: 20644159
    [No Abstract]   [Full Text] [Related]  

  • 7. [Anti-angiogenesis treatment for brain tumors: present and future].
    Takano S; Matsumura A
    No Shinkei Geka; 2006 Jul; 34(7):657-78. PubMed ID: 16841703
    [No Abstract]   [Full Text] [Related]  

  • 8. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
    Seystahl K; Weller M
    Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.
    Wilkes GM
    Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):54-6. PubMed ID: 19856612
    [No Abstract]   [Full Text] [Related]  

  • 10. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
    Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M
    Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in glioblastoma multiforme.
    Specenier P
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiogenesis and anti-angiogenic strategies for glioblastoma].
    de Boüard S; Guillamo JS
    Bull Cancer; 2005 Apr; 92(4):360-72. PubMed ID: 15888393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose antiangiogenic therapy for glioblastoma: less may be more?
    de Groot JF
    Clin Cancer Res; 2011 Oct; 17(19):6109-11. PubMed ID: 21852387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenic inhibition in high-grade gliomas: past, present and future.
    Jo J; Schiff D; Purow B
    Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab and recurrent malignant gliomas: a European perspective.
    Wick W; Weller M; van den Bent M; Stupp R
    J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions.
    Ahluwalia MS; Wen PY
    Expert Rev Anticancer Ther; 2011 May; 11(5):653-6. PubMed ID: 21554035
    [No Abstract]   [Full Text] [Related]  

  • 17. Taming glioblastoma by targeting angiogenesis: 3 years later.
    Wong ET; Brem S
    J Clin Oncol; 2011 Jan; 29(2):124-6. PubMed ID: 21135277
    [No Abstract]   [Full Text] [Related]  

  • 18. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.
    Sawlani RN; Raizer J; Horowitz SW; Shin W; Grimm SA; Chandler JP; Levy R; Getch C; Carroll TJ
    Radiology; 2010 May; 255(2):622-8. PubMed ID: 20413772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translating biological insights into clinical endpoints in neuro-oncology.
    Bredel M
    Lancet Oncol; 2009 Oct; 10(10):928-9. PubMed ID: 19628430
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH; Shen YL; Keegan P; Pazdur R
    Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.